Patrick Flynn

Audit Committee Chair

Mr. Flynn is a founding investor in NRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor. Pat currently serves as COO of Good Measures, Inc. He co-founded Predilytics, Inc., which was sold to Welltock, Inc. Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening its business in the GCC and China. Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.

Chaim Hurvitz

Mr. Chaim Hurvitz has served as the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd., from April 2002 to 2010 and was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University.

Jonathan C. Javitt, M.D., M.P.H.

Chairman and Chief Scientist

Dr. Javitt has been a founder of seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned by President Bush to Chair the Health Committee of the President’s Information Technology Advisory Committee (PITAC) and to lead the development of Executive Order 13335, establishing the Office of the National Coordinator for Health IT. In the aftermath of 9/11, Dr. Javitt was appointed a Senior Fellow in the National Security Health Policy Center of the Potomac Institute for Policy Studies to focus on biosecurity preparedness and appointed by President Bush to the Office of the Undersecretary of Defense. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins School of Medicine. The Harvard Chan School awarded him the Alumnus of Merit award in 2016 and he continues to serve as Adjunct Professor of the Johns Hopkins School of Medicine. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and Pharmacoeconomics that have been cited by more than 29,000 scientists. In his role as Chief Scientist of NRx Pharmaceuticals he continues to lead NRx on Scientific matters to advance and expand our pipeline of lifesaving medicines.

Stephen Willard

Chief Executive Officer & Director

Mr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price. Prior to Cellphire, he served as CEO of publicly traded Flamel Technologies now known as Avadel Pharmaceuticals. Mr. Willard is currently serving a six-year term from 2018-2024 as a presidential appointee to the National Science Board. Mr. Willard’s career in financial services includes government service as Associate Director of the Federal Deposit Insurance Corporation (FDIC), where he served in the United States Senior Executive Service (SES) from 1991-1994, and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and Washington, D.C. Mr. Willard earned his undergraduate degree from Williams College and attended Yale University where he earned a JD in law.

Janet Rehnquist

Corporate Governance

As an attorney with more than 25 years of experience in highly regulated industries, particularly healthcare, Ms. Rehnquist has developed a deep expertise in identifying, evaluating and mitigating risks for clients. Her primary responsibilities include advising clients on regulatory and compliance matters as well as governmental investigations. Notably, Ms. Rehnquist served as the Inspector General at the Department of Health and Human Services from 2001-2003, and has since interacted frequently with government regulators, including compliance and enforcement professionals, negotiated Corporate Integrity Agreements (CIAs) with the government and helped clients implement and monitor these agreements. Ms. Rehnquist earned a BA with honors from the University of Virginia (1979) and a JD from the University of Virginia School of Law (1985), where she was an editor of the Journal of Law and Politics.

Dennis K. McBride, Ph.D.

Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology, four master’s degrees, and an additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely and was elected by faculty in 1999 to full professor. Dr. McBride has served at multiple universities in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as an adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.

Prof. Daniel C. Javitt, M.D., Ph.D.

Co-founder & Chair, Scientific Advisory Board

Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuropsychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.

Philip T. Lavin, Ph.D.

Chief Methodologist

Dr. Lavin is a highly respected biostatistician with more than 30 years experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health, and a member of the Department of Surgery at Harvard Medical School where he was affiliated for more than 25 years. He co-founded Boston Biostatistics in 1983, a company known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 US Food and Drug Administration (FDA) approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years advising the FDA on complex statistical and policy issues.

Prof. Marion Leboyer, M.D., Ph.D

Principal Investigator (EU)

Marion Leboyer, M.D., Ph.D. is Professor of Psychiatry at the University of Paris Est Créteil (UPEC) in France. She is head of the DMU IMPACT (University-affiliated department of Psychiatry and Addictology (Hôpitaux Universitaires Mondor, Assistance-Publique-Hôpitaux de Paris). She also runs the laboratory “Translational NeuroPsychiatry” which is part of Mondor Institute for Biomedical research (IMRB, Inserm U955). Since 2007, she is the executive director of a non-profit foundation, “Fondation FondaMental” created by the French Ministry of Research. Dr. Leboyer has authored or co-authored more than 900 peer-reviewed international publications (H-index = 127) and is part of the highly cited researchers (Clarivate) since 2018. In 2022, she was ranked by Research.com best female scientist award (12 in France and 256 in the world among the Top Female Scientist). In December 2021, she received the Inserm Grand Prize. Her research efforts contributed to a better identification of genetic and environmental risk factors associated with major psychiatric disorders towards better understanding of causal mechanisms. In particular, she has contributed to the identification of associations of genetic vulnerability factors, of immune dysfunctions in major mood and psychotic disorders, but also of environmental risk factors as well as brain imaging abnormalities. Her goal is to develop biomarkers signatures to better identify homogenous subgroups of psychiatric disorders paving the way to mechanisms-based treatments. Within the 52 French expert center networks centers created and coordinated by Fondation FondaMental, several large and deeply phenotyped cohorts of patients have been followed allowing for the construction of shared observational databases and biobanks. These networks have enabled multiple collaborations within different national and international research programs. Dr Leboyer is the principal investigator of several international and national research projects.

Andrew Nierenberg, M.D.

Principal Investigator

Dr. Andrew Nierenberg has been at the Massachusetts General Hospital since 1992, where he holds his current positions. He is also Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong Australia. Dr. Nierenberg has published over 500 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. Klerman Young Investigator Award and in 2014 the Gerald L. Klerman Senior Investigator Award by the Depression Bipolar Support Alliance. In 2013, Dr. Nierenberg was awarded the prestigious Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research. In 2014, he was awarded the Mentorship Award for Exceptional Mentorship in the Research Arena at MGH. In 2014, 2015, and 2016 he was listed among the World’s Most Influential Scientific Minds by Thompson Reuters in recognition of ranking among the top 1% of researchers for most cited papers in psychiatry worldwide. Dr. Nierenberg’s primary interests are bipolar depression and novel treatments. He lectures extensively, teaches, supervises, and mentors junior faculty, has an active clinical practice, consults to industry, and conducts clinical trials funded by federal, foundation, industry, and philanthropic sources. He serves as a peer reviewer for over 35 psychiatric journals. Dr. Nierenberg is a member of the editorial boards of over 15 journals and is the editor of Psychiatric Annals and is a deputy editor of Depression and Anxiety.

Wayne Pines

Regulatory & Patient Advocacy Advisor

Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.